{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:39:23Z","timestamp":1793320763866,"version":"4.5.0"},"reference-count":175,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>Motor neuron diseases are sporadic or inherited fatal neurodegenerative conditions. They selectively affect the upper and\/or lower motor neurons in the brain and spinal cord and feature a slow onset and a subacute course contingent upon the site of damage. The main types include amyotrophic lateral sclerosis, progressive muscular atrophy, primary lateral sclerosis, and progressive bulbar palsy, the pathological processes of which are largely identical, with the main disparity lying in the location of the lesions. Amyotrophic lateral sclerosis is the representative condition in this group of diseases, while other types are its variants. Hence, this article mainly focuses on the advancements and challenges in drug research for amyotrophic lateral sclerosis but also briefly addresses several other important degenerative motor neuron diseases. Although the precise pathogenesis remains elusive, recent advancements have shed light on various theories, including gene mutation, excitatory amino acid toxicity, autoimmunology, and neurotrophic factors. The US Food and Drug Administration has approved four drugs for use in delaying the progression of amyotrophic lateral sclerosis: riluzole, edaravone, AMX0035, and tofersen, with the latter being the most recent to receive approval. However, following several phase III trials that failed to yield favorable outcomes, AMX0035 has been voluntarily withdrawn from both the US and Canadian markets. This article presents a comprehensive summary of drug trials primarily completed between January 1, 2023, and June 30, 2024, based on data sourced from clinicaltrials.gov. Among these trials, five are currently in phase I, seventeen are in phase II, and eleven are undergoing phase III evaluation. Notably, 24 clinical trials are now investigating potential disease-modifying therapy drugs, accounting for the majority of the drugs included in this review. Some promising drugs being investigated in preclinical studies, such as ATH-1105, are included in our analysis, and another review in frontiers in gene therapy and immunotherapy has demonstrated their therapeutic potential for motor neuron diseases. This article was written to be an overview of research trends and treatment prospects related to motor neuron disease drugs, with the aim of highlighting the latest potentialities for clinical therapy.<\/jats:p>","DOI":"10.4103\/nrr.nrr-d-24-01266","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T03:00:25Z","timestamp":1747191625000},"page":"1849-1863","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Latest progress and challenges in drug development for degenerative motor neuron diseases"],"prefix":"10.4103","volume":"21","author":[{"given":"Xiangjin","family":"Wen","sequence":"first","affiliation":[{"name":"Department of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China"},{"name":"West China School of Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxiang","family":"Lan","sequence":"additional","affiliation":[{"name":"Department of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China"},{"name":"West China School of Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4060-5736","authenticated-orcid":false,"given":"Yi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, West China College of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5603-4192","authenticated-orcid":false,"given":"Yongping","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"key":"R1-20260420","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/14728222.2020.1738390","article-title":"Silence superoxide dismutase 1 (SOD1): a promising therapeutic target for amyotrophic lateral sclerosis (ALS)","volume":"24","author":"Abati","year":"2020","journal-title":"Expert Opin Ther Targets"},{"key":"R2-20260420","doi-asserted-by":"crossref","first-page":"106050","DOI":"10.1016\/j.nbd.2023.106050","article-title":"Immunotherapy targeting the C-terminal domain of TDP-43 decreases neuropathology and confers neuroprotection in mouse models of ALS\/FTD","volume":"179","author":"Afroz","year":"2023","journal-title":"Neurobiol Dis"},{"key":"R3-20260420","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s41576-023-00592-y","article-title":"Amyotrophic lateral sclerosis: translating genetic discoveries into therapies","volume":"24","author":"Ak\u00e7imen","year":"2023","journal-title":"Nat Rev Genet"},{"key":"R4-20260420","article-title":"TPN-101","year":"2023"},{"key":"R5-20260420","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1016\/j.ymthe.2021.04.008","article-title":"Gene therapy for ALS: A review","volume":"29","author":"Amado","year":"2021","journal-title":"Mol Ther"},{"key":"R6-20260420","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1093\/brain\/awae109","article-title":"Apilimod dimesylate in C9orf72 amyotrophic lateral sclerosis: a randomized phase 2a clinical trial","volume":"147","author":"Babu","year":"2024","journal-title":"Brain"},{"key":"R7-20260420","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1038\/s41591-022-01956-3","article-title":"Transplantation of human neural progenitor cells secreting GDNF into the spinal cord of patients with ALS: a phase 1\/2a trial","volume":"28","author":"Baloh","year":"2022","journal-title":"Nat Med"},{"key":"R8-20260420","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1126\/science.abq5622","article-title":"Mechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies","volume":"379","author":"Baughn","year":"2023","journal-title":"Science"},{"key":"R9-20260420","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nature22038","article-title":"Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice","volume":"544","author":"Becker","year":"2017","journal-title":"Nature"},{"key":"R10-20260420","doi-asserted-by":"crossref","first-page":"1348157","DOI":"10.3389\/fnins.2024.1348157","article-title":"ATH-1105, a small-molecule positive modulator of the neurotrophic HGF system, is neuroprotective, preserves neuromotor function, and extends survival in preclinical models of ALS","volume":"18","author":"Berthiaume","year":"2024","journal-title":"Front Neurosci"},{"key":"R11-20260420","doi-asserted-by":"crossref","first-page":"6508","DOI":"10.1007\/s00415-024-12657-x","article-title":"Narrative review of diagnosis, management and treatment of dysphagia and sialorrhea in amyotrophic lateral sclerosis","volume":"271","author":"Bjelica","year":"2024","journal-title":"J Neurol"},{"key":"R12-20260420","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s40265-023-01904-6","article-title":"Tofersen: First approval","volume":"83","author":"Blair","year":"2023","journal-title":"Drugs"},{"key":"R13-20260420","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3389\/fncel.2017.00080","article-title":"ALS pathogenesis and therapeutic approaches: the role of mesenchymal stem cells and extracellular vesicles","volume":"11","author":"Bonafede","year":"2017","journal-title":"Front Cell Neurosci"},{"key":"R14-20260420","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.3390\/cells8091087","article-title":"The anti-apoptotic effect of ASC-exosomes in an in vitro ALS model and their proteomic analysis","volume":"8","author":"Bonafede","year":"2019","journal-title":"Cells"},{"key":"R15-20260420","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s004150200056","article-title":"Riluzole treatment in advanced ALS","volume":"249","author":"Borasio","year":"2002","journal-title":"J Neurol"},{"key":"R16-20260420","doi-asserted-by":"crossref","first-page":"eaau6414","DOI":"10.1126\/scitranslmed.aau6414","article-title":"Safe and effective superoxide dismutase 1 silencing using artificial microRNA in macaques","volume":"10","author":"Borel","year":"2018","journal-title":"Sci Transl Med"},{"key":"R17-20260420","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s13311-022-01247-2","article-title":"Antisense oligonucleotides for the study and treatment of ALS","volume":"19","author":"Boros","year":"2022","journal-title":"Neurotherapeutics"},{"key":"R18-20260420","doi-asserted-by":"crossref","first-page":"883","DOI":"10.3389\/fphar.2019.00883","article-title":"Ambroxol hydrochloride improves motor functions and extends survival in a mouse model of familial amyotrophic lateral sclerosis","volume":"10","author":"Bouscary","year":"2019","journal-title":"Front Pharmacol"},{"key":"R19-20260420","doi-asserted-by":"crossref","first-page":"173446","DOI":"10.1016\/j.ejphar.2020.173446","article-title":"Drug repositioning in neurodegeneration: An overview of the use of ambroxol in neurodegenerative diseases","volume":"884","author":"Bouscary","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"R20-20260420","doi-asserted-by":"crossref","first-page":"7781","DOI":"10.3390\/ijms22157781","article-title":"TDP-43 and inflammation: implications for amyotrophic lateral sclerosis and frontotemporal dementia","volume":"22","author":"Bright","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R21-20260420","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41586-022-04436-3","article-title":"TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A","volume":"603","author":"Brown","year":"2022","journal-title":"Nature"},{"key":"R22-20260420","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1159\/000516752","article-title":"Estimated prevalence and incidence of amyotrophic lateral sclerosis and SOD1 and C9orf72 genetic variants","volume":"55","author":"Brown","year":"2021","journal-title":"Neuroepidemiology"},{"key":"R23-20260420","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/brain\/awab423","article-title":"Antisense therapies in neurological diseases","volume":"145","author":"Brunet de Courssou","year":"2021","journal-title":"Brain"},{"key":"R24-20260420","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41419-020-2601-2","article-title":"Fine tuning of the unfolded protein response by ISRIB improves neuronal survival in a model of amyotrophic lateral sclerosis","volume":"11","author":"Bugallo","year":"2020","journal-title":"Cell Death Dis"},{"key":"R25-20260420","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1177\/1073858414561795","article-title":"SOD1 function and its implications for amyotrophic lateral sclerosis pathology: new and renascent themes","volume":"21","author":"Bunton-Stasyshyn","year":"2015","journal-title":"Neuroscientist"},{"key":"R26-20260420","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/WCO.0000000000001164","article-title":"Abnormal energy metabolism in ALS: a key player?","volume":"36","author":"Burg","year":"2023","journal-title":"Curr Opin Neurol"},{"key":"R27-20260420","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.3390\/ijms20184388","article-title":"Gene therapy for ALS-A perspective","volume":"20","author":"Cappella","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R28-20260420","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3233\/JND-200531","article-title":"Beyond the traditional clinical trials for amyotrophic lateral sclerosis and the future impact of gene therapy","volume":"8","author":"Cappella","year":"2021","journal-title":"J Neuromuscul Dis"},{"key":"R29-20260420","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1034\/j.1600-0714.2002.310505.x","article-title":"Progressive bulbar palsy: a case report diagnosed by lingual symptoms","volume":"31","author":"Cerero Lapiedra","year":"2002","journal-title":"J Oral Pathol Med"},{"key":"R30-20260420","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.2174\/092986710791163939","article-title":"Riluzole, neuroprotection and amyotrophic lateral sclerosis","volume":"17","author":"Cheah","year":"2010","journal-title":"Curr Med Chem"},{"key":"R31-20260420","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.bbrc.2020.03.051","article-title":"Ibudilast enhances the clearance of SOD1 and TDP-43 aggregates through TFEB-mediated autophagy and lysosomal biogenesis: The new molecular mechanism of ibudilast and its implication for neuroprotective therapy","volume":"526","author":"Chen","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"R32-20260420","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/jmedgenet-2021-107965","article-title":"Role of genetics in amyotrophic lateral sclerosis: a large cohort study in Chinese mainland population","volume":"59","author":"Chen","year":"2022","journal-title":"J Med Genet"},{"key":"R33-20260420","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3390\/ph14010029","article-title":"Role of edaravone as a treatment option for patients with amyotrophic lateral sclerosis","volume":"14","author":"Cho","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"R34-20260420","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.1038\/ncomms6845","article-title":"An acetylation switch controls TDP-43 function and aggregation propensity","volume":"6","author":"Cohen","year":"2015","journal-title":"Nat Commun"},{"key":"R35-20260420","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cmet.2018.03.004","article-title":"RNA-targeted therapeutics","volume":"27","author":"Crooke","year":"2018","journal-title":"Cell Metab"},{"key":"R36-20260420","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/d41573-023-00033-9","article-title":"PIKfyve inhibition rescues ALS pathology","volume":"22","author":"Crunkhorn","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"R37-20260420","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.3390\/ijms24043888","article-title":"Adipose-derived mesenchymal stromal cells in basic research and clinical applications","volume":"24","author":"Czerwiec","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R38-20260420","doi-asserted-by":"crossref","first-page":"113620","DOI":"10.1016\/j.expneurol.2021.113620","article-title":"Impairment of mitochondrial oxidative phosphorylation in skin fibroblasts of SALS and FALS patients is rescued by in vitro treatment with ROS scavengers","volume":"339","author":"Debska-Vielhaber","year":"2021","journal-title":"Exp Neurol"},{"key":"R39-20260420","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00702-019-02138-1","article-title":"Conservative iron chelation for neurodegenerative diseases such as Parkinson\u2019s disease and amyotrophic lateral sclerosis","volume":"127","author":"Devos","year":"2020","journal-title":"J Neural Transm (Vienna)"},{"key":"R41-20260420","article-title":"RAG-17: A novel siRNA conjugate demonstrating efficacy in late-stage treatment of SOD1G93A ALS mice","author":"Duan","year":"2023","journal-title":"bioRxiv [Preprint]"},{"key":"R42-20260420","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12916-024-03314-1","article-title":"TBK1, a prioritized drug repurposing target for amyotrophic lateral sclerosis: evidence from druggable genome Mendelian randomization and pharmacological verification in vitro","volume":"22","author":"Duan","year":"2024","journal-title":"BMC Med"},{"key":"R43-20260420","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1021\/acs.molpharmaceut.1c00297","article-title":"Non-viral vector-mediated gene therapy for ALS: challenges and future perspectives","volume":"18","author":"Ediriweera","year":"2021","journal-title":"Mol Pharm"},{"key":"R44-20260420","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nature09320","article-title":"Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS","volume":"466","author":"Elden","year":"2010","journal-title":"Nature"},{"key":"R45-20260420","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/ene.12664","article-title":"Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis","volume":"23","author":"Elia","year":"2016","journal-title":"Eur J Neurol"},{"key":"R46-20260420","article-title":"Pharmacological characterization of FC-12738: A novel retro-inverso pentapeptide for treating neuroinflammation","author":"Ellison","year":"2023","journal-title":"bioRxiv [Preprint]"},{"key":"R47-20260420","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1002\/med.21974","article-title":"Small molecules targeting different cellular pathologies for the treatment of amyotrophic lateral sclerosis","volume":"43","author":"Elmansy","year":"2023","journal-title":"Med Res Rev"},{"key":"R48-20260420","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.15252\/embj.201490493","article-title":"Dysregulated miRNA biogenesis downstream of cellular stress and ALS-causing mutations: a new mechanism for ALS","volume":"34","author":"Emde","year":"2015","journal-title":"EMBO J"},{"key":"R49-20260420","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00005-010-0063-4","article-title":"Lentiviral vectors in gene therapy: their current status and future potential","volume":"58","author":"Escors","year":"2010","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"R50-20260420","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/17582024.2024.2402216","article-title":"Tofersen for SOD1 ALS","volume":"14","author":"Everett","year":"2024","journal-title":"Neurodegener Dis Manag"},{"key":"R51-20260420","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3389\/fimmu.2019.00133","article-title":"Hide and seek: nanomaterial interactions with the immune system","volume":"10","author":"Fadeel","year":"2019","journal-title":"Front Immunol"},{"key":"R52-20260420","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.amjmed.2018.07.012","article-title":"Motor neuron disease: pathophysiology, diagnosis, and management","volume":"132","author":"Foster","year":"2019","journal-title":"Am J Med"},{"key":"R53-20260420","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1038\/mt.2013.211","article-title":"Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS","volume":"21","author":"Foust","year":"2013","journal-title":"Mol Ther"},{"key":"R54-20260420","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.3390\/cells11193153","article-title":"TFEB; Beyond its role as an autophagy and lysosomes regulator","volume":"11","author":"Franco-Ju\u00e1rez","year":"2022","journal-title":"Cells"},{"key":"R55-20260420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40261-022-01229-4","article-title":"Safety and efficacy of edaravone in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis","volume":"43","author":"Gao","year":"2023","journal-title":"Clin Drug Investig"},{"key":"R56-20260420","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.neuron.2019.02.038","article-title":"Cytoplasmic TDP-43 de-mixing independent of stress granules drives inhibition of nuclear import, loss of nuclear TDP-43, and cell death","volume":"102","author":"Gasset-Rosa","year":"2019","journal-title":"Neuron"},{"key":"R57-20260420","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/bab.2028","article-title":"Antisense oligonucleotide (AS-ODN) technology: principle, mechanism and challenges","volume":"68","author":"Gheibi-Hayat","year":"2021","journal-title":"Biotechnol Appl Biochem"},{"key":"R58-20260420","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41582-023-00867-2","article-title":"The amyotrophic lateral sclerosis exposome: recent advances and future directions","volume":"19","author":"Goutman","year":"2023","journal-title":"Nat Rev Neurol"},{"key":"R59-20260420","doi-asserted-by":"crossref","first-page":"137493","DOI":"10.1016\/j.neulet.2023.137493","article-title":"Protective effects of EVs\/exosomes derived from permanently growing human MSC on primary murine ALS motor neurons","volume":"816","author":"Gschwendtberger","year":"2023","journal-title":"Neurosci Lett"},{"key":"R60-20260420","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nature02870","article-title":"Unlocking the potential of the human genome with RNA interference","volume":"431","author":"Hannon","year":"2004","journal-title":"Nature"},{"key":"R61-20260420","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jbior.2015.10.006","article-title":"SOD1 in neurotoxicity and its controversial roles in SOD1 mutation-negative ALS","volume":"60","author":"Hayashi","year":"2016","journal-title":"Adv Biol Regul"},{"key":"R62-20260420","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1742-2094-3-2","article-title":"Primary glia expressing the G93A-SOD1 mutation present a neuroinflammatory phenotype and provide a cellular system for studies of glial inflammation","volume":"3","author":"Hensley","year":"2006","journal-title":"J Neuroinflammation"},{"key":"R63-20260420","doi-asserted-by":"crossref","first-page":"102441","DOI":"10.1016\/j.arr.2024.102441","article-title":"TDP-43 proteinopathy in frontotemporal lobar degeneration and amyotrophic lateral sclerosis: From pathomechanisms to therapeutic strategies","volume":"100","author":"Ho","year":"2024","journal-title":"Ageing Res Rev"},{"key":"R64-20260420","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.cell.2023.01.005","article-title":"PIKFYVE inhibition mitigates disease in models of diverse forms of ALS","volume":"186","author":"Hung","year":"2023","journal-title":"Cell"},{"key":"R65-20260420","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1172\/JCI44867","article-title":"Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice","volume":"121","author":"Igaz","year":"2011","journal-title":"J Clin Invest"},{"key":"R66-20260420","doi-asserted-by":"crossref","first-page":"101707","DOI":"10.1016\/j.eclinm.2022.101707","article-title":"Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial","volume":"53","author":"Imamura","year":"2022","journal-title":"EClinicalMedicine"},{"key":"R67-20260420","doi-asserted-by":"crossref","first-page":"eaaf3962","DOI":"10.1126\/scitranslmed.aaf3962","article-title":"The Src\/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis","volume":"9","author":"Imamura","year":"2017","journal-title":"Sci Transl Med"},{"key":"R68-20260420","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1212\/01.WNL.0000058901.75728.4E","article-title":"Corticospinal tract degeneration in the progressive muscular atrophy variant of ALS","volume":"60","author":"Ince","year":"2003","journal-title":"Neurology"},{"key":"R69-20260420","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/01616412.2016.1251711","article-title":"Oxidative stress and mitochondrial dysfunction-linked neurodegenerative disorders","volume":"39","author":"Islam","year":"2017","journal-title":"Neurol Res"},{"key":"R70-20260420","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1212\/CON.0000000000001345","article-title":"Amyotrophic lateral sclerosis and other motor neuron diseases","volume":"29","author":"Izenberg","year":"2023","journal-title":"Continuum (Minneap Minn)"},{"key":"R71-20260420","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.ncl.2015.07.010","article-title":"Symptom management and end-of-life care in amyotrophic lateral sclerosis","volume":"33","author":"Jackson","year":"2015","journal-title":"Neurol Clin"},{"key":"R72-20260420","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/med.21528","article-title":"Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs","volume":"39","author":"Jaiswal","year":"2019","journal-title":"Med Res Rev"},{"key":"R73-20260420","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.neuron.2016.04.006","article-title":"Gain of toxicity from ALS\/FTD-linked repeat expansions in C9ORF72 is alleviated by antisense oligonucleotides targeting GGGGCC-containing RNAs","volume":"90","author":"Jiang","year":"2016","journal-title":"Neuron"},{"key":"R74-20260420","doi-asserted-by":"crossref","first-page":"1054006","DOI":"10.3389\/fphar.2022.1054006","article-title":"New developments and opportunities in drugs being trialed for amyotrophic lateral sclerosis from 2020 to 2022","volume":"13","author":"Jiang","year":"2022","journal-title":"Front Pharmacol"},{"key":"R75-20260420","doi-asserted-by":"crossref","first-page":"5941","DOI":"10.1038\/s41598-020-62756-8","article-title":"Peripheral proinflammatory Th1\/Th17 immune cell shift is linked to disease severity in amyotrophic lateral sclerosis","volume":"10","author":"Jin","year":"2020","journal-title":"Sci Rep"},{"key":"R76-20260420","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/s12276-020-00513-7","article-title":"The role of TDP-43 propagation in neurodegenerative diseases: integrating insights from clinical and experimental studies","volume":"52","author":"Jo","year":"2020","journal-title":"Exp Mol Med"},{"key":"R77-20260420","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s40265-022-01769-1","article-title":"Pharmacotherapy for amyotrophic lateral sclerosis: a review of approved and upcoming agents","volume":"82","author":"Johnson","year":"2022","journal-title":"Drugs"},{"key":"R78-20260420","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/01.RES.86.5.580","article-title":"The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase","volume":"86","author":"Kantor","year":"2000","journal-title":"Circ Res"},{"key":"R79-20260420","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/neup.12716","article-title":"Astrocytes release glutamate via cystine\/glutamate antiporter upregulated in response to increased oxidative stress related to sporadic amyotrophic lateral sclerosis","volume":"40","author":"Kazama","year":"2020","journal-title":"Neuropathology"},{"key":"R80-20260420","doi-asserted-by":"crossref","first-page":"13909","DOI":"10.3390\/ijms140713909","article-title":"The efficacy of edaravone (radicut), a free radical scavenger, for cardiovascular disease","volume":"14","author":"Kikuchi","year":"2013","journal-title":"Int J Mol Sci"},{"key":"R81-20260420","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.neuron.2020.08.022","article-title":"ALS genetics: gains, losses, and implications for future therapies","volume":"108","author":"Kim","year":"2020","journal-title":"Neuron"},{"key":"R82-20260420","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1212\/WNL.0b013e3181c1dea3","article-title":"Study of 962 patients indicates progressive muscular atrophy is a form of ALS","volume":"73","author":"Kim","year":"2009","journal-title":"Neurology"},{"key":"R83-20260420","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41591-021-01615-z","article-title":"Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis","volume":"28","author":"Korobeynikov","year":"2022","journal-title":"Nat Med"},{"key":"R84-20260420","doi-asserted-by":"crossref","first-page":"111001","DOI":"10.1016\/j.celrep.2022.111001","article-title":"Loss of Stathmin-2, a hallmark of TDP-43-associated ALS, causes motor neuropathy","volume":"39","author":"Krus","year":"2022","journal-title":"Cell Rep"},{"key":"R85-20260420","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1089\/nat.2018.0721","article-title":"Lipid nanoparticles enabling gene therapies: from concepts to clinical utility","volume":"28","author":"Kulkarni","year":"2018","journal-title":"Nucleic Acid Ther"},{"key":"R86-20260420","first-page":"499","article-title":"Effects of Shakuyaku-kanzo-to (Tsumura TJ-68) on muscle cramps accompanying cirrhosis in a placebo-controlled double-blind parallel study","volume":"15","author":"Kumada","year":"1999","journal-title":"J Clin Therap Med (Rinsho Iyaku)"},{"key":"R87-20260420","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1089\/wound.2020.1175","article-title":"Adipose-derived mesenchymal stromal cells in regenerative medicine: state of play, current clinical trials, and future prospects","volume":"10","author":"Laloze","year":"2021","journal-title":"Adv Wound Care (New Rochelle)"},{"key":"R88-20260420","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1177\/1091581817740873","article-title":"Nonclinical development of ANX005: A humanized anti-C1q antibody for treatment of autoimmune and neurodegenerative diseases","volume":"36","author":"Lansita","year":"2017","journal-title":"Int J Toxicol"},{"key":"R89-20260420","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jphs.2018.10.008","article-title":"Inhibitory effects of Kampo medicines, Keishibukuryogan and Shakuyakukanzoto, on the substrate uptake activities of solute carrier organic anion transporters","volume":"138","author":"Lee","year":"2018","journal-title":"J Pharmacol Sci"},{"key":"R90-20260420","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1089\/ars.2011.4391","article-title":"The cystine\/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities","volume":"18","author":"Lewerenz","year":"2013","journal-title":"Antioxid Redox Signal"},{"key":"R92-20260420","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.ncl.2015.07.005","article-title":"Progressive muscular atrophy","volume":"33","author":"Liewluck","year":"2015","journal-title":"Neurol Clin"},{"key":"R93-20260420","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.neuron.2013.07.033","article-title":"Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis","volume":"79","author":"Ling","year":"2013","journal-title":"Neuron"},{"key":"R94-20260420","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.celrep.2019.04.003","article-title":"Loss of nuclear TDP-43 is associated with decondensation of LINE retrotransposons","volume":"27","author":"Liu","year":"2019","journal-title":"Cell Rep"},{"key":"R95-20260420","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.3389\/fimmu.2017.01005","article-title":"Role of neuroinflammation in amyotrophic lateral sclerosis: cellular mechanisms and therapeutic implications","volume":"8","author":"Liu","year":"2017","journal-title":"Front Immunol"},{"key":"R96-20260420","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.omtn.2022.04.007","article-title":"Preclinical evaluation of WVE-004, an investigational stereopure oligonucleotide for the treatment of C9orf72-associated ALS or FTD","volume":"28","author":"Liu","year":"2022","journal-title":"Mol Ther Nucl Acids"},{"key":"R97-20260420","doi-asserted-by":"crossref","first-page":"e00301","DOI":"10.1016\/j.neurot.2023.10.011","article-title":"Nicotinamide riboside, pterostilbene and ibudilast protect motor neurons and extend survival in ALS mice","volume":"21","author":"L\u00f3pez-Blanch","year":"2023","journal-title":"Neurotherapeutics"},{"key":"R98-20260420","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1038\/s41380-023-02036-9","article-title":"Early activation of cellular stress and death pathways caused by cytoplasmic TDP-43 in the rNLS8 mouse model of ALS and FTD","volume":"28","author":"Luan","year":"2023","journal-title":"Mol Psychiatry"},{"key":"R99-20260420","doi-asserted-by":"crossref","first-page":"22497","DOI":"10.1038\/s41598-023-49424-3","article-title":"The preferences of people with amyotrophic lateral sclerosis on riluzole treatment in Europe","volume":"13","author":"Ludolph","year":"2023","journal-title":"Sci Rep"},{"key":"R100-20260420","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.37765\/ajmc.2023.89389","article-title":"Optimizing pharmacologic treatment for ALS to improve outcomes and quality of life","volume":"29","author":"Lynch","year":"2023","journal-title":"Am J Manag Care"},{"key":"R101-20260420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1615\/CritRevImmunol.2023048372","article-title":"Personalized precision immunotherapy for amyotrophic lateral sclerosis (ALS)","volume":"43","author":"Maharaj","year":"2023","journal-title":"Crit Rev Immunol"},{"key":"R102-20260420","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-022-00612-2","article-title":"Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation","volume":"22","author":"Mead","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"R103-20260420","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1080\/21678421.2021.2023190","article-title":"Incidence of amyotrophic lateral sclerosis in the United States, 2014\u20132016","volume":"23","author":"Mehta","year":"2022","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"R104-20260420","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s13311-022-01285-w","article-title":"Approaches to gene modulation therapy for ALS","volume":"19","author":"Meijboom","year":"2022","journal-title":"Neurotherapeutics"},{"key":"R105-20260420","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.3389\/fnins.2019.01310","article-title":"ALS genetics, mechanisms, and therapeutics: Where are we now?","volume":"13","author":"Mejzini","year":"2019","journal-title":"Front Neurosci"},{"key":"R106-20260420","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1159\/000535749","article-title":"The effect of the oral iron chelator deferiprone on iron overload and oxidative stress in patients with myelodysplastic syndromes a study by the Israeli MDS Working Group","volume":"147","author":"Merkel","year":"2024","journal-title":"Acta Haematol"},{"key":"R107-20260420","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/mus.27818","article-title":"Neurofilament light-chain response during therapy with antisense oligonucleotide tofersen in SOD1-related ALS: Treatment experience in clinical practice","volume":"67","author":"Meyer","year":"2023","journal-title":"Muscle Nerve"},{"key":"R108-20260420","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2003715","article-title":"Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS","volume":"383","author":"Miller","year":"2020","journal-title":"N Engl J Med"},{"key":"R109-20260420","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of antisense oligonucleotide tofersen for SOD1 ALS","volume":"387","author":"Miller","year":"2022","journal-title":"N Engl J Med"},{"key":"R110-20260420","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/s13063-023-07424-8","article-title":"Randomized double-blind personalized N-of-1 clinical trial to test the safety and potential efficacy of TJ-68 for treating muscle cramps in amyotrophic lateral sclerosis (ALS): study protocol for a TJ-68 trial","volume":"24","author":"Mitsumoto","year":"2023","journal-title":"Trials"},{"key":"R112-20260420","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/21678421.2019.1632346","article-title":"Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial","volume":"21","author":"Mora","year":"2020","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"R113-20260420","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41587-021-00972-x","article-title":"Cholesterol-functionalized DNA\/RNA heteroduplexes cross the blood-brain barrier and knock down genes in the rodent CNS","volume":"39","author":"Nagata","year":"2021","journal-title":"Nat Biotechnol"},{"key":"R114-20260420","doi-asserted-by":"crossref","first-page":"1148444","DOI":"10.3389\/fnagi.2023.1148444","article-title":"Long-term survival benefits of intrathecal autologous bone marrow-derived mesenchymal stem cells (Neuronata-R\u00ae: lenzumestrocel) treatment in ALS: Propensity-score-matched control, surveillance study","volume":"15","author":"Nam","year":"2023","journal-title":"Front Aging Neurosci"},{"key":"R115-20260420","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1242\/jcs.146365","article-title":"TFEB at a glance","volume":"129","author":"Napolitano","year":"2016","journal-title":"J Cell Sci"},{"key":"R116-20260420","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1126\/science.1134108","article-title":"Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis","volume":"314","author":"Neumann","year":"2006","journal-title":"Science"},{"key":"R117-20260420","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.neulet.2006.10.024","article-title":"Edaravone inhibits lipid peroxidation in neonatal hypoxic-ischemic rats: An in vivo microdialysis study","volume":"414","author":"Noor","year":"2007","journal-title":"Neurosci Lett"},{"key":"R118-20260420","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/mus.27569","article-title":"Survival analyses from the CENTAUR trial in amyotrophic lateral sclerosis: Evaluating the impact of treatment crossover on outcomes","volume":"66","author":"Paganoni","year":"2022","journal-title":"Muscle Nerve"},{"key":"R119-20260420","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3390\/antiox11040614","article-title":"SOD1 in ALS: Taking stock in pathogenic mechanisms and the role of glial and muscle cells","volume":"11","author":"Peggion","year":"2022","journal-title":"Antioxidants (Basel)"},{"key":"R120-20260420","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nn.2779","article-title":"Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43","volume":"14","author":"Polymenidou","year":"2011","journal-title":"Nat Neurosci"},{"key":"R121-20260420","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00401-019-01962-9","article-title":"Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD","volume":"137","author":"Pottier","year":"2019","journal-title":"Acta Neuropathol"},{"key":"R122-20260420","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fnmol.2019.00025","article-title":"Molecular mechanisms of TDP-43 misfolding and pathology in amyotrophic lateral sclerosis","volume":"12","author":"Prasad","year":"2019","journal-title":"Front Mol Neurosci"},{"key":"R123-20260420","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/cpdd.747","article-title":"A pharmacokinetic bioequivalence study comparing sublingual riluzole (BHV-0223) and oral tablet formulation of riluzole in healthy volunteers","volume":"9","author":"Qureshi","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"R124-20260420","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1111\/bph.16408","article-title":"Montelukast improves disease outcome in SOD1(G93A) female mice by counteracting oligodendrocyte dysfunction and aberrant glial reactivity","volume":"181","author":"Raffaele","year":"2024","journal-title":"Br J Pharmacol"},{"key":"R125-20260420","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s13311-022-01253-4","article-title":"Immunoglobulin and monoclonal antibody therapies in Guillain-Barr\u00e9 syndrome","volume":"19","author":"Rajabally","year":"2022","journal-title":"Neurotherapeutics"},{"key":"R126-20260420","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nm1207","article-title":"Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS","volume":"11","author":"Raoul","year":"2005","journal-title":"Nat Med"},{"key":"R127-20260420","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s13311-015-0344-z","article-title":"RNA-targeted therapeutics for ALS","volume":"12","author":"Reddy","year":"2015","journal-title":"Neurotherapeutics"},{"key":"R128-20260420","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nn.3584","article-title":"State of play in amyotrophic lateral sclerosis genetics","volume":"17","author":"Renton","year":"2014","journal-title":"Nat Neurosci"},{"key":"R129-20260420","doi-asserted-by":"crossref","first-page":"e005213","DOI":"10.1136\/bmjopen-2014-005213","article-title":"Differential motor neuron involvement in progressive muscular atrophy: a comparative study with amyotrophic lateral sclerosis","volume":"4","author":"Riku","year":"2014","journal-title":"BMJ Open"},{"key":"R130-20260420","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrneurol.2017.148","article-title":"Antisense oligonucleotides: the next frontier for treatment of neurological disorders","volume":"14","author":"Rinaldi","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"R131-20260420","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1021\/bi026979d","article-title":"Tauroursodeoxycholic acid prevents Bax-induced membrane perturbation and cytochrome C release in isolated mitochondria","volume":"42","author":"Rodrigues","year":"2003","journal-title":"Biochemistry"},{"key":"R132-20260420","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1474-4422(14)70233-9","article-title":"C9orf72 expansions in frontotemporal dementia and amyotrophic lateral sclerosis","volume":"14","author":"Rohrer","year":"2015","journal-title":"Lancet Neurol"},{"key":"R133-20260420","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1080\/21678421.2023.2192247","article-title":"Clinical and demographical characteristics in a cohort of MND patients treated with riluzole. Differences between tablets and oral suspension","volume":"24","author":"Romero-Gangonells","year":"2023","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"R134-20260420","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/mus.21565","article-title":"Progressive muscular atrophy and other lower motor neuron syndromes of adults","volume":"41","author":"Rowland","year":"2010","journal-title":"Muscle Nerve"},{"key":"R135-20260420","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1080\/15548627.2018.1535292","article-title":"Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration","volume":"15","author":"Rusmini","year":"2019","journal-title":"Autophagy"},{"key":"R136-20260420","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s11418-008-0304-6","article-title":"Confirmation of the antispasmodic effect of shakuyaku-kanzo-to (TJ-68), a Chinese herbal medicine, on the duodenal wall by direct spraying during endoscopic retrograde cholangiopancreatography","volume":"63","author":"Sakai","year":"2009","journal-title":"J Nat Med"},{"key":"R137-20260420","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/21678421.2022.2119868","article-title":"Combination of ciprofloxacin\/celecoxib as a novel therapeutic strategy for ALS","volume":"24","author":"Salomon-Zimri","year":"2023","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"R138-20260420","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1146\/annurev-virology-031413-085355","article-title":"AAV-mediated gene therapy for research and therapeutic purposes","volume":"1","author":"Samulski","year":"2014","journal-title":"Annu Rev Virol"},{"key":"R139-20260420","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1111\/bph.15738","article-title":"Repurposing of Trimetazidine for amyotrophic lateral sclerosis: A study in SOD1(G93A) mice","volume":"179","author":"Scaricamazza","year":"2022","journal-title":"Br J Pharmacol"},{"key":"R140-20260420","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.3390\/ijms23052400","article-title":"Comprehensive research on past and future therapeutic strategies devoted to treatment of amyotrophic lateral sclerosis","volume":"23","author":"Sever","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R141-20260420","doi-asserted-by":"crossref","first-page":"105156","DOI":"10.1016\/j.nbd.2020.105156","article-title":"The genetic architecture of ALS","volume":"147","author":"Shatunov","year":"2021","journal-title":"Neurobiol Dis"},{"key":"R142-20260420","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/mus.26740","article-title":"Long-term edaravone efficacy in amyotrophic lateral sclerosis: Post-hoc analyses of Study 19 (MCI186-19)","volume":"61","author":"Shefner","year":"2020","journal-title":"Muscle Nerve"},{"key":"R143-20260420","doi-asserted-by":"crossref","first-page":"842","DOI":"10.3390\/ph15070842","article-title":"The protective effect of edaravone on TDP-43 plus oxidative stress-induced neurotoxicity in neuronal cells: analysis of its neuroprotective mechanisms using RNA sequencing","volume":"15","author":"Soejima-Kusunoki","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"R144-20260420","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.ncl.2015.07.007","article-title":"Primary lateral sclerosis","volume":"33","author":"Statland","year":"2015","journal-title":"Neurol Clin"},{"key":"R145-20260420","doi-asserted-by":"crossref","first-page":"103732","DOI":"10.1016\/j.ebiom.2021.103732","article-title":"Predictors of survival in patients with amyotrophic lateral sclerosis: A large meta-analysis","volume":"74","author":"Su","year":"2021","journal-title":"EBioMedicine"},{"key":"R146-20260420","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s12916-022-02411-3","article-title":"Genetic factors for survival in amyotrophic lateral sclerosis: an integrated approach combining a systematic review, pairwise and network meta-analysis","volume":"20","author":"Su","year":"2022","journal-title":"BMC Med"},{"key":"R147-20260420","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1080\/21678421.2022.2045323","article-title":"ALSUntangled #64: butyrates","volume":"23","author":"Sun","year":"2022","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"R148-20260420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14737175.2023.2174018","article-title":"An evaluation of the combination of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis","volume":"23","author":"Sun","year":"2023","journal-title":"Expert Rev Neurother"},{"key":"R149-20260420","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1080\/21678421.2023.2239292","article-title":"ALSUntangled #71: Nuedexta","volume":"25","author":"Sun","year":"2024","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"R150-20260420","doi-asserted-by":"crossref","first-page":"112025","DOI":"10.1016\/j.celrep.2023.112025","article-title":"FUS ALS neurons activate major stress pathways and reduce translation as an early protective mechanism against neurodegeneration","volume":"42","author":"Szewczyk","year":"2023","journal-title":"Cell Rep"},{"key":"R151-20260420","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/bph.12277","article-title":"Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis","volume":"170","author":"Takata","year":"2013","journal-title":"Br J Pharmacol"},{"key":"R152-20260420","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12974-016-0620-9","article-title":"Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis","volume":"13","author":"Trias","year":"2016","journal-title":"J Neuroinflammation"},{"key":"R153-20260420","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.brainres.2012.04.031","article-title":"Rodent models of TDP-43: recent advances","volume":"1462","author":"Tsao","year":"2012","journal-title":"Brain Res"},{"key":"R154-20260420","doi-asserted-by":"crossref","first-page":"1383453","DOI":"10.3389\/fmolb.2024.1383453","article-title":"Protein aggregation and therapeutic strategies in SOD1- and TDP-43-linked ALS","volume":"11","author":"Tsekrekou","year":"2024","journal-title":"Front Mol Biosci"},{"key":"R155-20260420","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1136\/jnnp-2019-322541","article-title":"Primary lateral sclerosis: consensus diagnostic criteria","volume":"91","author":"Turner","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R156-20260420","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3390\/jcm13020578","article-title":"Primary lateral sclerosis: an overview","volume":"13","author":"Vacchiano","year":"2024","journal-title":"J Clin Med"},{"key":"R157-20260420","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.molmed.2023.12.003","article-title":"The sense of antisense therapies in ALS","volume":"30","author":"Van Daele","year":"2024","journal-title":"Trends Mol Med"},{"key":"R158-20260420","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1474-4422(24)00216-3","article-title":"Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose study","volume":"23","author":"van den Berg","year":"2024","journal-title":"Lancet Neurol"},{"key":"R159-20260420","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1126\/science.1165942","article-title":"Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6","volume":"323","author":"Vance","year":"2009","journal-title":"Science"},{"key":"R160-20260420","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s12551-021-00902-w","article-title":"DICER: structure, function, and regulation","volume":"13","author":"Vergani-Junior","year":"2021","journal-title":"Biophys Rev"},{"key":"R161-20260420","doi-asserted-by":"crossref","first-page":"736","DOI":"10.3390\/cells12050736","article-title":"Current state and future directions in the diagnosis of amyotrophic lateral sclerosis","volume":"12","author":"Vidovic","year":"2023","journal-title":"Cells"},{"key":"R162-20260420","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1080\/13543784.2023.2263368","article-title":"Nanocrystalline gold (CNM-Au8): a novel bioenergetic treatment for ALS","volume":"32","author":"Vucic","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"key":"R163-20260420","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1097\/JOM.0000000000000323","article-title":"A meta-analysis of observational studies of the association between chronic occupational exposure to lead and amyotrophic lateral sclerosis","volume":"56","author":"Wang","year":"2014","journal-title":"J Occup Environ Med"},{"key":"R164-20260420","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.4103\/1673-5374.335827","article-title":"Advantages of Rho-associated kinases and their inhibitor fasudil for the treatment of neurodegenerative diseases","volume":"17","author":"Wang","year":"2022","journal-title":"Neural Regen Res"},{"key":"R165-20260420","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/nn.3514","article-title":"Interaction of FUS and HDAC1 regulates DNA damage response and repair in neurons","volume":"16","author":"Wang","year":"2013","journal-title":"Nat Neurosci"},{"key":"R166-20260420","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s12640-018-9865-7","article-title":"Autophagic modulation by trehalose reduces accumulation of TDP-43 in a cell model of amyotrophic lateral sclerosis via TFEB activation","volume":"34","author":"Wang","year":"2018","journal-title":"Neurotox Res"},{"key":"R167-20260420","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1001\/jamaneurol.2021.4893","article-title":"Safety and effectiveness of long-term intravenous administration of edaravone for treatment of patients with amyotrophic lateral sclerosis","volume":"79","author":"Witzel","year":"2022","journal-title":"JAMA Neurol"},{"key":"R168-20260420","doi-asserted-by":"crossref","first-page":"E3","DOI":"10.1073\/pnas.1321248111","article-title":"Role for terminal complement activation in amyotrophic lateral sclerosis disease progression","volume":"111","author":"Woodruff","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R169-20260420","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.3390\/antiox10071012","article-title":"Amyotrophic lateral sclerosis: molecular mechanisms, biomarkers, and therapeutic strategies","volume":"10","author":"Yang","year":"2021","journal-title":"Antioxidants (Basel)"},{"key":"R170-20260420","first-page":"53","article-title":"Amyotrophic lateral sclerosis and its mimics\/variants: a comprehensive review","volume":"8","author":"Yedavalli","year":"2018","journal-title":"J Clin Imaging Sci"},{"key":"R171-20260420","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.3390\/molecules25092193","article-title":"Therapeutic nanoparticles and their targeted delivery applications","volume":"25","author":"Yetisgin","year":"2020","journal-title":"Molecules"},{"key":"R172-20260420","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.3390\/ijms21113801","article-title":"CRISPR\/Cas9-mediated gene correction to understand ALS","volume":"21","author":"Yun","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R173-20260420","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.clinthera.2016.12.014","article-title":"Target intestinal microbiota to alleviate disease progression in amyotrophic lateral sclerosis","volume":"39","author":"Zhang","year":"2017","journal-title":"Clin Ther"},{"key":"R174-20260420","doi-asserted-by":"crossref","first-page":"e0223232","DOI":"10.1371\/journal.pone.0223232","article-title":"Enhanced anti-tumor effect of liposomal Fasudil on hepatocellular carcinoma in vitro and in vivo","volume":"14","author":"Zhao","year":"2019","journal-title":"PLoS One"},{"key":"R175-20260420","doi-asserted-by":"crossref","first-page":"e10919","DOI":"10.15252\/emmm.201910919","article-title":"Active poly-GA vaccination prevents microglia activation and motor deficits in a C9orf72 mouse model","volume":"12","author":"Zhou","year":"2020","journal-title":"EMBO Mol Med"},{"key":"R176-20260420","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.apsb.2022.07.019","article-title":"Honokiol alleviated neurodegeneration by reducing oxidative stress and improving mitochondrial function in mutant SOD1 cellular and mouse models of amyotrophic lateral sclerosis","volume":"13","author":"Zhou","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"R177-20260420","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41593-020-0619-5","article-title":"Reduced C9ORF72 function exacerbates gain of toxicity from ALS\/FTD-causing repeat expansion in C9orf72","volume":"23","author":"Zhu","year":"2020","journal-title":"Nat Neurosci"},{"key":"R178-20260420","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.pneurobio.2016.05.004","article-title":"ALS: A bucket of genes, environment, metabolism and unknown ingredients","volume":"142","author":"Zufir\u00eda","year":"2016","journal-title":"Prog Neurobiol"}],"container-title":["Neural Regeneration Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/NRR.NRR-D-24-01266","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:22:01Z","timestamp":1787836921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/NRR.NRR-D-24-01266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":175,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/nrr.nrr-d-24-01266","relation":{},"ISSN":["1673-5374","1876-7958"],"issn-type":[{"value":"1673-5374","type":"print"},{"value":"1876-7958","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]},"assertion":[{"value":"2024-10-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}